Heska Corp (HSKA) 52.49 $HSKA Illumina Keen on Genome

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Heska Corp (HSKA) 52.49 $HSKA

Illumina Keen on Genome Network Growth & Global Expansion
Zacks Equity Research - Zacks Investment Research - Fri Aug 26, 2:23PM CDT
On Aug 25, 2016, we issued an updated research report on Illumina Inc. (ILMN).
HSKA: 52.49 (-0.27), ILMN: 167.90 (-0.66), ANIK: 47.89 (-0.05)

Align Technology's Invisalign Dependence: Boon or Curse?
Zacks Equity Research - Zacks Investment Research - Wed Aug 17, 5:15PM CDT
Align Technology (ALGN) ended the second-quarter 2016 on a promising note, squarely beating the Zacks Consensus Estimate.
ALGN: 95.78 (+2.02), HSKA: 52.49 (-0.27), ANIP: 59.86 (-1.56), ANIK: 47.89 (-0.05)

FDA Approves Edwards Lifesciences' Intuity Elite Heart Valve
Zacks Equity Research - Zacks Investment Research - Wed Aug 17, 5:12PM CDT
Edwards' (EW) Intuity Elite valve system is used to treat patients suffering from coronary artery disease and are required to undergo aortic valve replacement surgery.
HSKA: 52.49 (-0.27), ANIP: 59.86 (-1.56), EW: 115.85 (-0.02), ANIK: 47.89 (-0.05)

Myriad Genetics: Q4 Hit by Low Test Revenues, Gross Margin
Zacks Equity Research - Zacks Investment Research - Tue Aug 16, 7:38AM CDT
Myriad (MYGN) ended fiscal 2016 on a disappointing note, with its fourth-quarter numbers missing the Zacks Consensus Estimate on both fronts.
MYGN: 20.65 (+0.21), HSKA: 52.49 (-0.27), ANIP: 59.86 (-1.56), ANIK: 47.89 (-0.05)

MEDNAX (MD) Acquires Anesthesiology Practice in Nevada
Zacks Equity Research - Zacks Investment Research - Mon Aug 15, 9:33AM CDT
MEDNAX recently announced the acquisition of a private physician group practice -- Associated Anesthesiologists -- in Reno, Nevada.
BABY: 40.64 (+0.93), MASI: 59.90 (+0.47), HSKA: 52.49 (-0.27), MD: 66.57 (+2.09)

PharMerica (PMC) Q2 Earnings in Line, Revenues Beat
Zacks Equity Research - Zacks Investment Research - Thu Aug 11, 7:16AM CDT
PharMerica reported second-quarter 2016 adjusted earnings of 47 cents per share.
PMC: 25.95 (+0.76), BABY: 40.64 (+0.93), MASI: 59.90 (+0.47), HSKA: 52.49 (-0.27)

Heska (HSKA) Shares March Higher, Can It Continue?
Zacks Equity Research - Zacks Investment Research - Wed Aug 10, 8:56AM CDT
As of late, it has definitely been a great time to be an investor in Heska Corp (HSKA).
HSKA: 52.49 (-0.27)

BioTelemetry (BEAT) Q2 Earnings, Revenues Beat; View Up
Zacks Equity Research - Zacks Investment Research - Tue Aug 09, 8:25AM CDT
BioTelemetry Inc. reported strong second-quarter 2016 adjusted earnings of 20 cents per share.
BABY: 40.64 (+0.93), MASI: 59.90 (+0.47), HSKA: 52.49 (-0.27), BEAT: 18.82 (+0.12)

Arena's (ARNA) Q2 Loss Narrower, Revenues Increase Y/Y
Arpita Dutt - Zacks Investment Research - Tue Aug 09, 6:19AM CDT
Arena (ARNA) continues to work on the advancement of its proprietary pipeline candidates.
HSKA: 52.49 (-0.27), CBM: 43.27 (+0.10), ANIP: 59.86 (-1.56), ARNA: 1.57 (+0.01)

Kite Pharma (KITE) Q2 Loss Wider but Focus is on KTE-C19
Arpita Dutt - Zacks Investment Research - Tue Aug 09, 5:44AM CDT
Although Kite's (KITE) Q2 loss was wider-than-expected, investor focus remains primarily on the company's progress with KTE-C19.
HSKA: 52.49 (-0.27), CBM: 43.27 (+0.10), KITE: 58.76 (-0.11), AMGN: 169.77 (-0.36)

Heska to Present at Canaccord Genuity 36th Annual Growth Conference on August 10, 2016
PR Newswire - Thu Aug 04, 11:00AM CDT
Heska Corporation (NASDAQ: HSKA - News; "Heska" or the "Company", a provider of advanced veterinary diagnostic and specialty products, today announced Kevin Wilson, Chief Executive Officer and President, will present at the Canaccord Genuity 36th Annual Growth Conference on Wednesday, August 10, 2016 at 4:30 p.m. ET.
HSKA: 52.49 (-0.27)

Heska Reports Record Second Quarter Results
PR Newswire - Wed Aug 03, 8:00AM CDT
Heska Corporation (NASDAQ: HSKA - News; "Heska" or the "Company", a provider of advanced veterinary diagnostic and specialty products, today reported financial results for its second quarter ended June 30, 2016.
HSKA: 52.49 (-0.27)

Webcast Alert: Heska Announces Second Quarter 2016 Earnings Conference Call Webcast
PR Newswire - Tue Aug 02, 8:00AM CDT
Heska Corporation (Nasdaq: HSKA) announces the following Webcast:
HSKA: 52.49 (-0.27)

Heska (HSKA) Sees Hammer Chart Pattern: Time to Buy?
Zacks Equity Research - Zacks Investment Research - Wed Jun 15, 8:54AM CDT
Heska Corporation (HSKA) has been struggling lately, but the selling pressure may be coming to an end soon
HSKA: 52.49 (-0.27)

New Strong Buy Stocks for June 2nd
Swarup Gupta - ZACKS - Thu Jun 02, 8:30AM CDT
New Strong Buy Stocks for June 2nd
HSKA: 52.49 (-0.27), FMBH: 25.17 (+0.02), DISCA: 25.89 (+0.20), LXFR: 11.69 (+0.05), BNS: 54.33 (+0.71)

Galena Biopharma (GALE) in Focus: Stock Moves Up 19.3%
Zacks Equity Research - Zacks Investment Research - Thu Jun 02, 7:15AM CDT
Galena Biopharma, Inc. (GALE) shares rose over 19% in the last trading session.
HSKA: 52.49 (-0.27), GALE: 0.40 (unch)

Edge Therapeutics (EDGE) Catches Eye: Stock Soars 19.4%
Zacks Equity Research - Zacks Investment Research - Thu Jun 02, 7:00AM CDT
Edge Therapeutics, Inc (EDGE) was a big mover last session, as the company's shares rose over 19% on the day.
HSKA: 52.49 (-0.27), EDGE: 8.95 (-0.04)

Integra Unveils Fin-Lock Glenoid, Boosts Shoulder Arthroplasty
Zacks Equity Research - Zacks Investment Research - Tue May 24, 7:22AM CDT
Integra LifeSciences Holdings Corporation (IART) recently launched Integra Fin-Lock Glenoid.
IART: 87.17 (+0.39), HSKA: 52.49 (-0.27), ANIP: 59.86 (-1.56), NEO: 8.00 (+0.05)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Evotec’s $2.9M Grant Advances Drug Safety Tech

Updated Category News Views 87

Revitalizing Drug Development with Human Stem Cells Evotec's latest win—a crisp $2.9 million grant from the Gates Foundation—is like a shot of adrenaline for drug safety innovation. This isn't just another drop in the bucket; it's a solid boost toward improving how we screen potential drugs for fetal risks before they're tossed into the costly whirlpool of clinical...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 399

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 448

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
Segway Powersports Dominates Baja 1000 with Class 2 Sweep

Updated Category News Views 72

Catching the eye of any betting man, Segway Powersports has turned its maiden outing at the relentless SCORE Baja 1000 into a rousing victory. Their arrival on this unforgiving stage with a one-two in Class 2 isn't just a lucky roll—you don't chance upon podium sweeps in such gritty contests. Dissecting the Drive: Commitment and Coordination Unfolding across Baja's...

Continue Reading
Pollo AI Unveils York AI: Automating Social Growth

Updated Category News Views 0

York AI Debuts as the New Kid on the Block Amid the hustle and bustle of a tech-savvy Singapore, Pollo AI’s latest offering, York AI, sashays onto the scene with the promise of putting social media growth on cruise control. We're talking about a digital sidekick that seems to know your online persona better than you do. It’s tailored for everyone from the small-time...

Continue Reading
Ascletis' Preclinical Successes: Future of Obesity Treatment

Updated Category News Views 14

Pharma Giants Eyeing a New Potential Well, it seems the world of pharma is buzzing with Ascletis’ latest developments in the obesity treatment arena. They’ve just showcased some intriguing preclinical data at ObesityWeek® 2026. The standout? A cocktail of advancements that might just put a dent in the obesity epidemic if further studies pan out. ASC30_48: A Daily...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 412

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Fapon's MEDICA 2026 Bid: Game-Changer or Same Old?

Updated Category News Views 89

Fapon's Ambitious Pitch at MEDICA: A Real Deal? MEDICA 2026 sees Fapon stepping up, laden with flashy promises and hardened expertise. Set up in Düsseldorf, these folks are pushing their Local Manufacturing Solutions harder than a door-to-door vacuum seller. The main pitch? Bolstering local IVD production with their comprehensive tech transfer services. How many outfits...

Continue Reading
Local Voices to Shape Mekong's Story in New Alliance

Updated Category News Views 284

Unpacking the New Storytelling Strategy Right off the bat, let's make it clear—this isn't just another run-of-the-mill environmental project announcement. When the National Geographic Society teams up with ThaiBev to empower Southeast Asian storytellers, they're not just waving around the usual conservation banner. Instead, they're betting on local voices to lead the...

Continue Reading
Akeso's Gumokimab Wins NMPA Approval for AS Treatment

Updated Category News Views 115

Gumokimab Approved: A New Dawn in AS Treatment Yeah, the biotech world shifts gears today as Akeso's gumokimab received the green light from China's National Medical Products Administration (NMPA). This approval for treating ankylosing spondylitis, or AS, isn't just another checkbox for Akeso; it's a game-changer in tackling this chronic inflammatory disease. Why should...

Continue Reading

Top 5 Most Recently Viewed Articles

O-I Glass Announces Participation in Citi’s 2025 Conference

Updated Category News Views 208

O-I Glass Participation in the 2025 Basic Materials Conference PERRYSBURG, Ohio — O-I Glass, Inc., known for its commitment to creating exceptional glass products, is set to participate in the upcoming Citi’s 2025 Basic Materials Conference. This significant event will take place on a Wednesday in December, and features notable presentations from O-I's leadership....

Continue Reading
Osmium Partners Proposes Strategic Plan for Articore Growth

Updated Category News Views 104

Osmium Partners Proposes a Four-Step Plan for Articore Osmium Partners has recently made headlines with their proposal for Articore, aiming to elevate shareholder value through a methodical four-step approach. This initiative is driven by Osmium's belief that Articore's current management strategy lacks direction and has resulted in missed opportunities for growth and...

Continue Reading
Amplify Energy Set to Shine at EnerCom Denver Conference 2025

Updated Category News Views 135

Amplify Energy’s Participation in EnerCom Denver Conference Amplify Energy Corp. is gearing up to participate in the renowned annual EnerCom Denver Conference in 2025. This event, known for bringing together leading experts and investors in the energy sector, offers Amplify a prime platform to showcase its strategic initiatives and growth potential. Focus on Investor...

Continue Reading
Safe Life Expands CPR Training and AED Services through Acquisition

Updated Category News Views 197

Safe Life Strengthens National Coverage for Life-Saving Training Safe Life has made a significant move by acquiring HeartCert, a company known for its specialization in automated external defibrillators (AEDs) and CPR training. This acquisition allows Safe Life to broaden its reach into the Midwest, enhancing its commitment to providing life-saving training and equipment...

Continue Reading
Express Scripts Challenges FTC's Drug Pricing Conclusions

Updated Category News Views 106

Express Scripts Files Lawsuit Against the FTC Express Scripts, a major player in the pharmacy benefit manager sector, has recently taken legal action against the U.S. Federal Trade Commission (FTC). This lawsuit stems from a report that criticizes the role of pharmacy benefit managers in the pricing of medications. Express Scripts contends that the report's conclusions...

Continue Reading